<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426904</url>
  </required_header>
  <id_info>
    <org_study_id>KNUHCRC006</org_study_id>
    <nct_id>NCT03426904</nct_id>
  </id_info>
  <brief_title>Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer</brief_title>
  <official_title>Neoadjuvant Chemotherapy for Non-metastatic Locally Advanced Colon Cancer: A Prospective Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyungpook National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main cause of recurrence after surgical treatment of colon cancer is distant metastasis.&#xD;
      Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of&#xD;
      chemotherapy. Preoperative chemotherapy may eradicate microscopic metastatic cancer cells&#xD;
      earlier than adjuvant chemotherapy, reduce cancer cell spillage during surgery, and lessen&#xD;
      the invasiveness of surgical resection. This randomized multicenter phase III trial is&#xD;
      assessing whether preoperative chemotherapy improves oncologic outcomes of patients with&#xD;
      locally advanced colon cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse free survival after randomization</measure>
    <time_frame>3 years after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 year after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological assessment of response to neoadjuvant treatment</measure>
    <time_frame>6 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological assessment of response to neoadjuvant treatment</measure>
    <time_frame>1 months after surgery</time_frame>
    <description>Replacement of the tumor by fibrous or fibro-inflammatory granulation tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complication</measure>
    <time_frame>60 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>60 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC QLQ-C30)</measure>
    <time_frame>before treatment, before surgery, 3 months after surgery, 6 months after surgery, 1 year after surgery</time_frame>
    <description>QLQ (quality of life questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC QLQ-C38)</measure>
    <time_frame>before treatment, before surgery, 3 months after surgery, 6 months after surgery, 1 year after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of chemotherapy</measure>
    <time_frame>1 year</time_frame>
    <description>Toxicity : incidence of chemotherapy-related adverse events according to CTCAE (Common Terminology Criteria for Adverse Events) v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of completion of chemotherapy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of CT staging</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cycles of perioperative chemotherapy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological tumor stage</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Colon cancer stage by AJCC 8th edition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of FOLFOX (Folinic acid, fluorouracil and oxaliplatin) neoadjuvant followed by surgery and 8 cycles of FOLFOX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional adjuvant FOLFOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>surgery followed by 12 cycles of FOLFOX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant FOLFOX</intervention_name>
    <description>4 cycles of FOLFOX neoadjuvant chemotherapy and 8 cycles of postoperative chemotherapy</description>
    <arm_group_label>Neoadjuvant FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional adjuvant FOLFOX</intervention_name>
    <description>12 cycles of postoperative FOLFOX chemotherapy</description>
    <arm_group_label>Conventional adjuvant FOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed colon adenocarcinoma (&gt; 15 cm from the anal verge)&#xD;
&#xD;
          -  Radiologic T3/T4 and high risk features by CT scan&#xD;
&#xD;
          -  No metastasis on CT or PET(positron emission computed tomography)&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 70 years&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) performance status 0-1&#xD;
&#xD;
          -  No history of colorectal cancer within 5 years&#xD;
&#xD;
          -  No history of chemotherapy&#xD;
&#xD;
          -  Patients with childbearing potential should use effective contraception during the&#xD;
             study and the following 6 months&#xD;
&#xD;
          -  Adequate bone marrow function : white blood cell count of 2 x 109/L or more with&#xD;
             neutrophils of1.5 x 109/L or more, platelet count of 100 x 109/L or more, hemoglobin&#xD;
             of 9 g/dL (5,6 mmol/l) or more&#xD;
&#xD;
          -  Adequate hepatobiliary function : total bilirubin of 0.4 mg/dl or less, ASAT&#xD;
             (aspartate aminotransferase) and ALAT (alanine aminotransferase) of 2.5 x ULN (upper&#xD;
             limits of normal) or less, Alkaline phosphatase of 1.5 x ULN or less&#xD;
&#xD;
          -  Adequate renal function : GFR (Glomerular Filtration Rate) &gt; 50ml/min by Wright or&#xD;
             Cockcroft formula&#xD;
&#xD;
          -  Signed written informed consent obtained prior to any study specific screening&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 70 years and &lt; 18 years&#xD;
&#xD;
          -  Rectal cancer : 15 cm or less from the anal verge&#xD;
&#xD;
          -  Complicated colon cancer (complete obstruction, perforation, bleeding)&#xD;
&#xD;
          -  Metastatic colon cancer&#xD;
&#xD;
          -  Known hypersensitivity reaction to any of the components of study treatments&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Hereditary nonpolyposis colorectal cancerHNPCC, familial Adenomatous Polyposis&#xD;
&#xD;
          -  Clinically relevant coronary artery disease or history of myocardial infarction in the&#xD;
             last 6 months, high risk of uncontrolled arrhythmia&#xD;
&#xD;
          -  Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption&#xD;
&#xD;
          -  Pregnancy or breast-feeding period&#xD;
&#xD;
          -  Serious non-healing wound or bone fracture&#xD;
&#xD;
          -  Medical, geographical, sociological, psychological or legal conditions that would not&#xD;
             permit the patient to complete the study or sign informed consent&#xD;
&#xD;
          -  Any significant disease which, in the investigator's opinion, would exclude the&#xD;
             patient from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Yeun Park, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kyungpook National University Chilgok Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gyu-Seog Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Chilgok Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soo Yeun Park, MD</last_name>
    <phone>+82-53-200-2166</phone>
    <email>psy-flower@daumm.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gyu-Seog Choi, MD, PhD</last_name>
    <phone>+82-53-200-2166</phone>
    <email>kyuschoi@mail.knu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Chonnam</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Hyun Kim, MD</last_name>
      <email>cksantiago8@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chang Hyun Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyong Rok Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Yeun Park, MD</last_name>
      <email>psy-flower@daum.net</email>
    </contact>
    <investigator>
      <last_name>Soo Yeun Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gyu-Seog Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Seog Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hye Jin Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In Ja Park, MD</last_name>
      <email>ipark@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>In Ja Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic Univ. of Korea St. Vincent's Hospital</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bong-Hyeon Kye, M.D.</last_name>
      <email>ggbong@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hyeon Min Cho, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>December 20, 2020</last_update_submitted>
  <last_update_submitted_qc>December 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University Hospital</investigator_affiliation>
    <investigator_full_name>Gyu-Seog Choi</investigator_full_name>
    <investigator_title>Kyungpook National University Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

